MedDataX Logo

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

NCT ID: NCT00230789

Last Updated: 2021-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

417 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

NCT00143481

Urinary Incontinence
COMPLETED PHASE4

A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

NCT00645281

Urinary Bladder, Overactive
COMPLETED PHASE4

Detrol LA In Men With Overactive Bladder.

NCT00282932

Overactive Bladder (OAB)
COMPLETED PHASE4

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

NCT01302938

Overactive Bladder
TERMINATED PHASE4

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)

NCT01488578

Overactive Bladder
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tolterodine ER 4 mg QD

Intervention Type DRUG

OAB Patient Behavioral Training Material

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects greater than or equal to 18 years of age
* Overactive bladder symptoms for at least 3 months
* Previously treated with antimuscarinic OAB medications

Exclusion Criteria

* Participation in any professionally coached sessions (RN, NP, PA or PT) teaching behavioral interventions
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Sun Lakes, Arizona, United States

Site Status

Pfizer Investigational Site

Little Rock, Arkansas, United States

Site Status

Pfizer Investigational Site

Beverly Hills, California, United States

Site Status

Pfizer Investigational Site

Buena Park, California, United States

Site Status

Pfizer Investigational Site

Mission Viejo, California, United States

Site Status

Pfizer Investigational Site

Modesto, California, United States

Site Status

Pfizer Investigational Site

Oceanside, California, United States

Site Status

Pfizer Investigational Site

Paramount, California, United States

Site Status

Pfizer Investigational Site

Sacramento, California, United States

Site Status

Pfizer Investigational Site

Torrance, California, United States

Site Status

Pfizer Investigational Site

Tustin, California, United States

Site Status

Pfizer Investigational Site

Colorado Springs, Colorado, United States

Site Status

Pfizer Investigational Site

Wheat Ridge, Colorado, United States

Site Status

Pfizer Investigational Site

Hallandale, Florida, United States

Site Status

Pfizer Investigational Site

Orlando, Florida, United States

Site Status

Pfizer Investigational Site

Wellington, Florida, United States

Site Status

Pfizer Investigational Site

Woodstock, Georgia, United States

Site Status

Pfizer Investigational Site

Libertyville, Illinois, United States

Site Status

Pfizer Investigational Site

Mattoon, Illinois, United States

Site Status

Pfizer Investigational Site

Newton, Kansas, United States

Site Status

Pfizer Investigational Site

Milford, Massachusetts, United States

Site Status

Pfizer Investigational Site

Manchester, Missouri, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Westhampton, New Jersey, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Albany, New York, United States

Site Status

Pfizer Investigational Site

Endwell, New York, United States

Site Status

Pfizer Investigational Site

Garden City, New York, United States

Site Status

Pfizer Investigational Site

Poughkeepsie, New York, United States

Site Status

Pfizer Investigational Site

The Bronx, New York, United States

Site Status

Pfizer Investigational Site

Greensboro, North Carolina, United States

Site Status

Pfizer Investigational Site

Hickory, North Carolina, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Canton, Ohio, United States

Site Status

Pfizer Investigational Site

Zanesville, Ohio, United States

Site Status

Pfizer Investigational Site

Norman, Oklahoma, United States

Site Status

Pfizer Investigational Site

Abington, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Bala-Cynwyd, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Camp Hill, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Williamsport, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Mt. Pleasant, South Carolina, United States

Site Status

Pfizer Investigational Site

Simpsonville, South Carolina, United States

Site Status

Pfizer Investigational Site

Bartlett, Tennessee, United States

Site Status

Pfizer Investigational Site

Johnson City, Tennessee, United States

Site Status

Pfizer Investigational Site

New Tazewell, Tennessee, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Provo, Utah, United States

Site Status

Pfizer Investigational Site

Mountlake Terrace, Washington, United States

Site Status

Pfizer Investigational Site

Spokane, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6121146&StudyName=Effect+Of+Detrol+LA+with+Behavioral+Intervention+In+Overactive+Bladder+Subjects+Dissatisfied+with+Recent+OAB+Medication%2E

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A6121146

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
NCT03492281 COMPLETED PHASE3
Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
NCT00143377 COMPLETED PHASE4
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
NCT00439192 TERMINATED PHASE2
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
NCT01175382 COMPLETED PHASE2/PHASE3
Effects Of Detrol LA On Memory And Cognition In Elderly Population
NCT00411437 COMPLETED PHASE4
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
NCT00730535 COMPLETED PHASE4
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
NCT00293839 COMPLETED PHASE3
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
NCT00139724 COMPLETED PHASE3
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
NCT00137397 COMPLETED PHASE4
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
NCT03583372 COMPLETED PHASE3
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
NCT00481728 COMPLETED PHASE1
Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder
NCT00836381 COMPLETED PHASE4
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
NCT01302054 COMPLETED PHASE4
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
NCT00768521 COMPLETED PHASE1
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
NCT01089751 COMPLETED PHASE4
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
NCT02138747 COMPLETED PHASE4
Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome
NCT00313924 UNKNOWN PHASE4
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
NCT00802373 COMPLETED PHASE3
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01604928 COMPLETED PHASE2
Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity
NCT00648310 COMPLETED PHASE2/PHASE3
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
NCT01314872 COMPLETED PHASE2
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
NCT00928070 COMPLETED PHASE4
Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder
NCT00746681 COMPLETED PHASE2
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
NCT00127270 COMPLETED PHASE4
Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
NCT04090190 COMPLETED PHASE4